Clinical Trials
3 trialsNCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT03901378 2021-01-25
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Ochsner Health System
Phase 2 Withdrawn